Aluda was founded around the idea that we need new approaches to drug discovery to find fundamentally new categories and identify better, more powerful intervention points against disease.

Aluda has five in vivo models providing POC of this Treg activator role for ALD-R491 and all point to clinical utility across multiple autoimmune indications.

Expert on vimentin structural biology, history, and safety with specialization in cancer. Publication with Aluda in 2023 on mechanical change of vimentin filaments in the presence of Aluda drug. » Read more

Aluda selected by California Life Sciences in August 2023 as a top 10 startup, earning spot in the FAST incubator Fall 2023 cohort, from 50+ applicants. Expert advisory team of top executives from biotech and big pharma engaged for 4 month intensive.

Aluda proof of principle data: Psoriasis, Multiple Sclerosis, Graft versus Host Disease, Type 1 diabetes, Lupus Transplant and Graft versus Host. and more, as well as providing important utility in transplantation and cancer.

Vimentin the facility for change provides an ideal access to block severe stages of disease where multiple features are driven by multiple components. In most Aluda indications this is 70% of the market or higher.

Inhibition of exosomes appears to offer a promising and highly novel intervention in cancer. Aluda has proven that its vimentin binding small molecules, including ALD-R491, can intervene in the biogenesis and release of exosomes in tumor cells, with no …

Innovation and collaboration are our core values at Aluda Pharmaceuticals. We are seeking highly extraordinary and dedicated individuals to join our team and help us develop drug candidates and technologies for the benefit of health and society.

Aluda is developing vimentin inhibitors for idiopathic pulmonary fibrosis (IPF) and other fibrotic conditions, including non-lung fibrosis.

Aluda Pharmaceuticals, Inc. 1080 Marsh Road, Suite 200 Menlo Park, CA 94025. Telephone: +1 (650) 260-5860 Email: [email protected]. This document was printed from http://www.aludapharm.com/contact/index.html